Published in Biophys J on September 01, 1998
The structural basis of antibody-antigen recognition. Front Immunol (2013) 1.14
The association of heavy and light chain variable domains in antibodies: implications for antigen specificity. FEBS J (2011) 1.05
Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires. Proc Natl Acad Sci U S A (2016) 0.90
Probing the stability-limiting regions of an antibody single-chain variable fragment: a molecular dynamics simulation study. Protein Eng Des Sel (2011) 0.88
Advances in Antibody Design. Annu Rev Biomed Eng (2015) 0.80
Co-evolution of affinity and stability of grafted amyloid-motif domain antibodies. Protein Eng Des Sel (2015) 0.80
Bispecific antibodies in cancer immunotherapy. Hum Vaccin Immunother (2016) 0.80
Shape complementarity and hydrogen bond preferences in protein-protein interfaces: implications for antibody modeling and protein-protein docking. Bioinformatics (2016) 0.76
Expression, production, and renaturation of a functional single-chain variable antibody fragment (scFv) against human ICAM-1. Braz J Med Biol Res (2014) 0.75
Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. MAbs (2016) 0.75
Determinants of the assembly and function of antibody variable domains. Sci Rep (2017) 0.75
The relation between the divergence of sequence and structure in proteins. EMBO J (1986) 16.66
Denaturant m values and heat capacity changes: relation to changes in accessible surface areas of protein unfolding. Protein Sci (1995) 9.23
Single-chain antigen-binding proteins. Science (1988) 5.29
Phosphocholine binding immunoglobulin Fab McPC603. An X-ray diffraction study at 2.7 A. J Mol Biol (1986) 4.16
Folding and association of proteins. Prog Biophys Mol Biol (1987) 3.53
A relationship between protein stability and protein function. Proc Natl Acad Sci U S A (1995) 3.44
Mutant forms of staphylococcal nuclease with altered patterns of guanidine hydrochloride and urea denaturation. Proteins (1986) 2.23
Domain association in immunoglobulin molecules. The packing of variable domains. J Mol Biol (1985) 2.03
Three-state analysis of sperm whale apomyoglobin folding. Biochemistry (1993) 1.96
A simple model for proteins with interacting domains. Applications to scanning calorimetry data. Biochemistry (1989) 1.88
Conformational stability of dimeric proteins: quantitative studies by equilibrium denaturation. Protein Sci (1994) 1.83
Analysis of binding in macromolecular complexes: a generalized numerical approach. Anal Biochem (1990) 1.70
Stability and function: two constraints in the evolution of barstar and other proteins. Structure (1994) 1.67
Unfolding free energy changes determined by the linear extrapolation method. 2. Incorporation of delta G degrees N-U values in a thermodynamic cycle. Biochemistry (1988) 1.62
A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry (1990) 1.60
Staphylococcal nuclease: a showcase of m-value effects. Adv Protein Chem (1995) 1.51
High resolution functional analysis of antibody-antigen interactions. J Mol Biol (1992) 1.49
Reconstitution of lactic dehydrogenase. Noncovalent aggregation vs. reactivation. 1. Physical properties and kinetics of aggregation. Biochemistry (1979) 1.49
Renaturation of Escherichia coli tryptophanase after exposure to 8 M urea. Evidence for the existence of nucleation centers. Eur J Biochem (1974) 1.43
Extrapolation to water of kinetic and equilibrium data for the unfolding of barnase in urea solutions. Protein Eng (1994) 1.34
Engineered turns of a recombinant antibody improve its in vivo folding. Protein Eng (1995) 1.31
Improvements in the numerical analysis of thermodynamic data from biomolecular complexes. Anal Biochem (1993) 1.22
Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli. Biochemistry (1991) 1.18
Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry (1994) 1.06
Sequence determinants of folding and stability for the P22 Arc repressor dimer. FASEB J (1996) 1.02
Recognition and interactions controlling the assemblies of beta barrel domains. Biophys J (1986) 0.99
Unfolding and refolding of a type kappa immunoglobulin light chain and its variable and constant fragments. Biochemistry (1987) 0.99
Noncovalent association of heavy and light chains of human immunoglobulins. III. Specific interactions between VH and VL. J Immunol (1982) 0.99
Equilibrium and kinetic aspects of the interaction of isolated variable and constant domains of light chain with the Fd' fragment of immunoglobulin G. Biochemistry (1979) 0.98
An antibody that facilitates hematopoietic engraftment recognizes CD44. Blood (1990) 0.98
Folding nuclei of the scFv fragment of an antibody. Biochemistry (1996) 0.94
Dissociation and denaturation equilibria and kinetics of a homogeneous human immunoglobulin Fab fragment. Biochemistry (1976) 0.93
Folding and interaction of subunits at the antibody combining site. Biochemistry (1976) 0.91
Equilibrium and kinetics of the denaturation of a homogeneous human immunoglobulin light chain. Biochemistry (1973) 0.90
Characterization of a quaternary-structured folding intermediate of an antibody Fab-fragment. Protein Sci (1995) 0.88
Characterization of an anti-CD44 single-chain FV antibody that stimulates natural killer cell activity and induces TNF alpha release. Immunol Invest (1995) 0.78
Relative conformational stabilities of single-chain pocket and groove-shaped antibody active sites including HCDR transplant intermediates. Biochemistry (1995) 0.77
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
The relationship between ligand-binding thermodynamics and protein-ligand interaction forces measured by atomic force microscopy. Biophys J (1995) 2.15
Structural studies of the streptavidin binding loop. Protein Sci (1997) 2.07
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92
Site-directed mutagenesis studies of the high-affinity streptavidin-biotin complex: contributions of tryptophan residues 79, 108, and 120. Proc Natl Acad Sci U S A (1995) 1.89
Engineered chimeric streptavidin tetramers as novel tools for bioseparations and drug delivery. Biotechnology (N Y) (1995) 1.78
The design and synthesis of polymers for eukaryotic membrane disruption. J Control Release (1999) 1.77
Energetic roles of hydrogen bonds at the ureido oxygen binding pocket in the streptavidin-biotin complex. Biochemistry (1998) 1.69
Thermodynamic and structural consequences of flexible loop deletion by circular permutation in the streptavidin-biotin system. Protein Sci (1998) 1.54
pH-responsive polymeric micelle carriers for siRNA drugs. Biomacromolecules (2010) 1.52
Ser45 plays an important role in managing both the equilibrium and transition state energetics of the streptavidin-biotin system. Protein Sci (2000) 1.51
Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia (2006) 1.51
A structural snapshot of an intermediate on the streptavidin-biotin dissociation pathway. Proc Natl Acad Sci U S A (1999) 1.50
Chimeric peptides of statherin and osteopontin that bind hydroxyapatite and mediate cell adhesion. J Biol Chem (2000) 1.46
Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant (2006) 1.29
A peptide that inhibits hydroxyapatite growth is in an extended conformation on the crystal surface. Proc Natl Acad Sci U S A (1998) 1.25
Structural studies of binding site tryptophan mutants in the high-affinity streptavidin-biotin complex. J Mol Biol (1998) 1.23
Structure and dynamics of hydrated statherin on hydroxyapatite as determined by solid-state NMR. Biochemistry (2001) 1.20
Dissociation of tetrameric ions of noncovalent streptavidin complexes formed by electrospray ionization. J Am Soc Mass Spectrom (1995) 1.16
Characterization of monoclonal antibodies that recognize canine CD34. Blood (1998) 1.13
A pH-sensitive polymer that enhances cationic lipid-mediated gene transfer. Bioconjug Chem (2001) 1.10
Mesenchymal stem cells as vehicles for gene delivery. Clin Orthop Relat Res (2000) 1.09
Hemolytic activity of pH-responsive polymer-streptavidin bioconjugates. Bioconjug Chem (1999) 1.03
Theratope vaccine (STn-KLH). Expert Opin Biol Ther (2001) 1.03
Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol (2005) 1.02
Decreased rejection and improved survival of first and second marrow transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood (1998) 1.00
Size-dependent control of the binding of biotinylated proteins to streptavidin using a polymer shield. Nature (2001) 0.96
differential L-selectin binding activities of human hematopoietic cell L-selectin ligands, HCELL and PSGL-1. J Biol Chem (2001) 0.95
Temperature control of biotin binding and release with A streptavidin-poly(N-isopropylacrylamide) site-specific conjugate. Bioconjug Chem (1999) 0.95
Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin. Bioconjug Chem (1997) 0.95
Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant (2005) 0.93
Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. J Clin Pharmacol (2013) 0.93
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant (2000) 0.93
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy. Bone Marrow Transplant (2011) 0.93
Time-resolved fluorescence studies of genetically engineered Escherichia coli glutamine synthetase. Effects of ATP on the tryptophan-57 loop. Biochemistry (1991) 0.92
Structural studies of biomaterials using double-quantum solid-state NMR spectroscopy. Annu Rev Phys Chem (2002) 0.91
Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant (2010) 0.91
Mechanistic investigation of smart polymer-protein conjugates. Bioconjug Chem (2001) 0.91
DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood (1995) 0.91
Founder's Award, Society for Biomaterials. Sixth World Biomaterials Congress 2000, Kamuela, HI,May 15-20, 2000. Really smart bioconjugates of smart polymers and receptor proteins. J Biomed Mater Res (2000) 0.90
Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens. Bone Marrow Transplant (2008) 0.89
Site-specific polymer-streptavidin bioconjugate for pH-controlled binding and triggered release of biotin. Bioconjug Chem (2000) 0.88
'Resistance' to unrelated, DLA-nonidentical canine marrow grafts is unrestricted by the major histocompatibility complex. Exp Hematol (1994) 0.87
The use of an anti-TCRalphabeta monoclonal antibody to control host-versus-graft reactions in canine marrow allograft recipients conditioned with low dose total body irradiation. Transplantation (1999) 0.87
What radiation dose for DLA-identical canine marrow grafts? Blood (1988) 0.87
Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP. Blood (1992) 0.87
Development of new biotin/streptavidin reagents for pretargeting. Biomol Eng (1999) 0.86
Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant (2012) 0.86
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Stem Cells (1996) 0.86
Protein electrostatic surface distribution can determine whether calcium oxalate crystal growth is promoted or inhibited. Calcif Tissue Int (1999) 0.86
Genetic engineering of redox donor sites: measurement of intracomplex electron transfer between ruthenium-65-cytochrome b5 and cytochrome c. Biochemistry (1992) 0.85
Mutagenesis of cytochromes P450cam and b5. Methods Enzymol (1991) 0.85
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia (2005) 0.84
X-ray crystallographic studies of streptavidin mutants binding to biotin. Biomol Eng (1999) 0.84
Atomic resolution structure of biotin-free Tyr43Phe streptavidin: what is in the binding site? Acta Crystallogr D Biol Crystallogr (1999) 0.84
Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia. Pediatr Hematol Oncol (2012) 0.84
Streptavidin in antibody pretargeting. 2. Evaluation Of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity. Bioconjug Chem (1998) 0.84
Site-specific conjugation of a temperature-sensitive polymer to a genetically-engineered protein. Bioconjug Chem (1995) 0.83
Thermoprecipitation of streptavidin via oligonucleotide-mediated self-assembly with poly(N-isopropylacrylamide). Bioconjug Chem (1999) 0.83
Nanoparticle distribution during systemic inflammation is size-dependent and organ-specific. Nanoscale (2015) 0.82
Enhancement of natural killer activity by an antibody to CD44. J Immunol (1993) 0.82
Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin. Bone Marrow Transplant (2012) 0.82
Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. Immunotechnology (1998) 0.82
Current and future preparative regimens for bone marrow transplantation in thalassemia. Ann N Y Acad Sci (1998) 0.82
Stimulation of canine hematopoiesis by recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol (1989) 0.81
Solid-state NMR structural studies of peptides immobilized on gold nanoparticles. Langmuir (2005) 0.81
Engineering protein orientation at surfaces to control macromolecular recognition events. Anal Chem (1993) 0.81
Late failure of autologous marrow grafts in lethally irradiated dogs given anti-class II monoclonal antibody. Blood (1991) 0.81
Prevention of graft-versus-host disease. Studies in a canine model. Ann N Y Acad Sci (1995) 0.80
An antibody to CD44 enhances hematopoiesis in long-term marrow cultures. Exp Hematol (1996) 0.79
Streptavidin in antibody pretargeting. Comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins. Bioconjug Chem (1998) 0.79
Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting. Ann N Y Acad Sci (1999) 0.79
Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century. Transplant Proc (2000) 0.79
Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes. Blood (2001) 0.79
Constrained cell recognition peptides engineered into streptavidin. Biotechnol Prog (1999) 0.79
Characterization of an anti-CD44 single-chain FV antibody that stimulates natural killer cell activity and induces TNF alpha release. Immunol Invest (1995) 0.78
Extracorporeal photopheresis in addition to pentostatin in conditioning for canine hematopoietic cell transplantation: role in engraftment. Bone Marrow Transplant (2010) 0.78
The expression and differentiation pattern of cell antigens and adhesion molecules on the nonadherent cell population in canine long-term marrow culture: a biphasic development of myeloid and lymphoid cells. Tissue Antigens (1998) 0.77
Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century. Front Biosci (2001) 0.77
Non-myeloablative hematopoietic stem cell transplantation. Transfus Clin Biol (2001) 0.76
Mechanisms of enhancement of natural killer activity by an antibody to CD44: increase in conjugate formation and release of tumor necrosis factor alpha. Cell Immunol (1995) 0.76
The influence of transfusions from unrelated DLA-matched or mismatched donors upon marrow grafts between DLA-identical canine littermates. Transplantation (1988) 0.76
Dynamic intracellular delivery of antibiotics via pH-responsive polymersomes. Polym Chem (2015) 0.76
T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma. Cytotherapy (2002) 0.75
Failure of interleukin-1 and granulocyte-macrophage colony-stimulating factor to enhance allogeneic marrow engraftment and survival in irradiated dogs. Blood (1995) 0.75
Biophysics. May the force be with you. Nature (1999) 0.75
CD8+ activated T lymphocytes produce an in vitro skin graft-versus-host reaction in an organotypic skin culture model. Transplantation (1995) 0.75
Antibody engagement of intercellular adhesion molecule 3 triggers apoptosis of normal and leukaemic myeloid marrow cells. Br J Haematol (2000) 0.75
Expression and characterization of human salivary statherin from Escherichia coli using two different fusion constructs. Protein Expr Purif (1999) 0.75
An organotypic skin culture model in dogs. A model for transplantation immunopathology in canine systems. Transplantation (1994) 0.75
Engineering two-dimensional protein order at surfaces. J Pharm Sci (1997) 0.75
Two-dimensional crystallization of streptavidin: in pursuit of the molecular origins of structure, morphology, and thermodynamics. Biomol Eng (1999) 0.75